Contrasting Nyxoah (NASDAQ:NYXH) and DarioHealth (NASDAQ:DRIO)

Nyxoah (NASDAQ:NYXH) and DarioHealth (NASDAQ:DRIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Nyxoah and DarioHealth, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
DarioHealth	0	0	1	0	3.00

Nyxoah presently has a consensus price target of $17.00, suggesting a potential upside of 55.82%. DarioHealth has a consensus price target of $4.00, suggesting a potential upside of 476.37%. Given DarioHealth’s higher probable upside, analysts plainly believe DarioHealth is more favorable than Nyxoah.

Profitability

This table compares Nyxoah and DarioHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
DarioHealth	-205.62%	-72.16%	-40.74%

Valuation & Earnings

This table compares Nyxoah and DarioHealth”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.87)	-5.83
DarioHealth	$20.35 million	1.16	-$59.43 million	($0.94)	-0.74

Nyxoah has higher earnings, but lower revenue than DarioHealth. Nyxoah is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nyxoah has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Institutional and Insider Ownership

33.4% of DarioHealth shares are held by institutional investors. 16.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DarioHealth beats Nyxoah on 8 of the 12 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.